INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio Pharmaceuticals (INO) shares rose 20.6% after the FDA agreed to a rolling Biologics License Application (BLA) submission for INO-3107, its investigational DNA medicine for recurrent respiratory papillomatosis (RRP). The company aims to finalize the BLA in the coming months and seek priority review, potentially shortening the FDA's review period to six months for a possible 2026 launch. INO-3107, which has breakthrough therapy and orphan drug designations, is advancing based on positive Phase I/II data, although Precigen recently secured full FDA approval for its competing RRP treatment, Papzimeos.

Analysis

Inovio Pharmaceuticals (INO) experienced a significant 20.6% stock price increase following the FDA's agreement to a rolling Biologics License Application (BLA) submission for INO-3107, its drug candidate for recurrent respiratory papillomatosis (RRP). This regulatory milestone, supported by positive Phase I/II study data, de-risks the development timeline, with the company targeting a finalized submission in the coming months, potential FDA acceptance by year-end 2025, and a commercial launch in 2026. The plan to seek Priority Review, which would shorten the review period to six months, further highlights a potentially expedited path to market, building on the drug's existing Breakthrough Therapy and Orphan Drug designations. However, this positive momentum is significantly tempered by the competitive landscape. Precigen (PGEN) recently secured full FDA approval for its RRP treatment, Papzimeos, granting it a crucial first-mover advantage. Notably, Precigen's full approval does not require a post-launch confirmatory study, whereas Inovio is still gearing up to initiate one for INO-3107, suggesting a more complex and costly path to securing a final, unencumbered market position.

Key Decisions for Investors

• While the FDA's acceptance of a rolling BLA for INO-3107 provides a clear set of positive catalysts for Inovio through 2025, investors must price in the significant competitive threat from Precigen's already-approved Papzimeos.
• Monitor Inovio's progress on key milestones, specifically the official BLA submission, the FDA's decision on granting Priority Review, and the initiation and design of the required confirmatory study, as these will directly impact the drug's commercial potential.
• Given Precigen's first-mover advantage with a fully approved drug, investors should critically assess the potential market share INO-3107 can realistically capture if it launches in 2026 or later.